Citation Impact
Citing Papers
Short Preoperative Treatment With Erlotinib Inhibits Tumor Cell Proliferation in Hormone Receptor–Positive Breast Cancers
2008
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
2016 Standout
Mechanisms of Endocrine Resistance in Breast Cancer
2010
Framing international trade and chronic disease
2011 Standout
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
Phosphorylation of FOXO3a on Ser-7 by p38 Promotes Its Nuclear Localization in Response to Doxorubicin
2011
EGFR associated expression profiles vary with breast tumor subtype
2007
Using quantitative and qualitative data in health services research – what happens when mixed method findings conflict? [ISRCTN61522618]
2006
Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function
2008
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
2020 Standout
Top 10 Challenges in Cancer Immunotherapy
2020
Estrogen Receptors: How Do They Signal and What Are Their Targets
2007 Standout
Targeted therapies in breast cancer: are heart and vessels also being targeted?
2012
Do physiotherapists’ attitudes towards evidence‐based practice change as a result of an evidence‐based educational programme?
2004
β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer
2012
The social construction of chronicity – a key to understanding chronic care transformations
2009
Quality of care: the need for medical, contextual and policy evidence in primary care
2005
Wnt signaling in cancer
2016 Standout
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib
2006
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
2012 StandoutNature
Development of an evidence‐based practice questionnaire for nurses
2006 Standout
Basal-like breast cancer and the BRCA1 phenotype
2006
Allergic Rhinitis and Its Impact on Asthma
2001 Standout
Growth factor signalling in endocrine and anti-growth factor resistant breast cancer
2007
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
2010 Standout
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Including qualitative research in systematic reviews: opportunities and problems
2001
Improving the Quality of Health Care in the United Kingdom and the United States: A Framework for Change
2001 Standout
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Evidence‐based practice in primary care: past, present and future
1996
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
2005 Standout
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
2005
Oxidative Stress: Harms and Benefits for Human Health
2017 Standout
The Mistreatment of Women during Childbirth in Health Facilities Globally: A Mixed-Methods Systematic Review
2015 Standout
Reviewing audit: barriers and facilitating factors for effective clinical audit
2000
Conducting a critical interpretive synthesis of the literature on access to healthcare by vulnerable groups
2006 Standout
Evidence-based medicine: a commentary on common criticisms.
2000
Natural Polyphenols for Prevention and Treatment of Cancer
2016 Standout
Evidence‐based medicine: a Kuhnian perspective of a transvestite non‐theory
1998
The care of the patient and the soul of the clinic: person-centered medicine as an emergent model of modern clinical practice
2011
Hesperetin Induces Apoptosis in Breast Carcinoma by Triggering Accumulation of ROS and Activation of ASK1/JNK Pathway
2014
Scoping studies: towards a methodological framework
2005 Standout
Flavonoids in Cancer and Apoptosis
2018 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Drug Resistance in Cancer: An Overview
2014 Standout
Educational Policy and Accreditation Standards
2001 Standout
The Quality and Effectiveness of Care Provided by Nurse Practitioners
2013 Standout
Achieving Integration in Mixed Methods Designs—Principles and Practices
2013 Standout
Works of Andreas Polychronis being referenced
Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer
2009
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial
2005
Clinical audit in the National Health Service: fact or fiction?
1996
Medicine and evidence: knowledge and action in clinical practice
2007
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
2018
Developments in the evidence‐based health care debate – 2004
2004
Evidence‐based medicine: why all the fuss? This is why
1997
Current thinking in the evidence‐based health care debate
2003
The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells
2007